Overview of Slow Deralin

Quick Facts

Property	Description
Active Ingredient	Propranolol (hydrochloride)
Form	Sustained-release capsule
Pharmacological Class	Non-selective beta-blocker
Route of Administration	Oral
Origin	Synthetic compound

What Type of Medicine is Slow Deralin?

Slow Deralin is a prescription-only medicine (POM) featuring Propranolol (Propranolol hydrochloride) as its active component. This medication is formally classified as a non-selective beta-adrenergic receptor blocking agent, widely recognized in clinical practice as a beta-blocker. As a chemically synthesized compound, its primary function is to block the effects of stress hormones, particularly adrenaline, on specific beta-receptors throughout the body. Propranolol is an agent used to manage conditions related to the sympathetic nervous system, reflecting its broad role in moderating physiological stress responses.

Composition and the Sustained-Release Formulation

The product contains Propranolol hydrochloride as its sole active ingredient, delivered in a specialized sustained-release capsule. This particular format, designated by the term "Slow," is a key differentiating feature that sets it apart from immediate-release formulations. The capsule is an oral modified-release formulation engineered to release the Propranolol gradually over many hours. This controlled, prolonged administration is specifically designed to facilitate the maintenance of a stable therapeutic concentration in the bloodstream, contributing to consistent patient management.

What is the General Therapeutic Purpose of Slow Deralin?

The general therapeutic purpose of Slow Deralin is to stabilize and regulate cardiovascular functions influenced by sympathetic nervous system activity. The action of Propranolol reduces the heart's workload by slowing the rate and force of contraction. This mechanism is fundamental to promoting a steady, more regular heart rhythm and achieving consistent modulation of blood pressure, serving as a cornerstone treatment for various conditions where the heart requires reduced stimulation.

What side effects are possible with Slow Deralin?

Possible Side Effects and Safety Information

The safety profile of Slow Deralin (propranolol hydrochloride) is documented by regulatory authorities and includes adverse reactions grouped by frequency and affected body system.

Adverse Reactions and Side Effects

Adverse reactions are classified into categories such as More common (e.g., tiredness, dizziness, cold hands or feet, sleep disturbances, nausea) and Less serious (e.g., rash, dry eyes, hair loss).

Serious adverse reactions, which require immediate medical attention, include severe allergic reactions (anaphylaxis, swelling of the face, lips, or tongue), severe slow heart rate (bradycardia), heart failure (indicated by sudden weight gain, swelling, or shortness of breath), severe low blood pressure, and bronchospasm (difficulty breathing or wheezing), particularly in patients with pre-existing lung conditions like asthma.

System/Organ Class	Examples of Documented Side Effects
Cardiovascular	Slow heart rate, low blood pressure, heart block.
Nervous System	Tiredness, dizziness, disturbed sleep, depression.
Gastrointestinal	Nausea, vomiting, diarrhea, abdominal pain.

Contraindications and Safety Restrictions

The medicine is contraindicated (must not be used) in patients with conditions such as bronchial asthma, cardiogenic shock, certain degrees of heart block (greater than first degree, unless a pacemaker is present), severe slow heartbeat, and overt heart failure.

Abrupt discontinuation of this medication may lead to serious heart problems, including the worsening of chest pain (angina) or myocardial infarction (heart attack). The dosage must be gradually reduced over one to two weeks before stopping treatment.

Population-Specific Cautions

Caution is advised for use in patients with liver or kidney impairment, as removal of the drug from the body may be slowed. In patients with diabetes, this medicine can mask symptoms of low blood sugar (hypoglycemia), such as a rapid heart rate, increasing the risk of a severe hypoglycemic event. Regulatory documents also note the drug's use during pregnancy and breastfeeding may be associated with unwanted effects in the fetus or newborn, requiring consultation with a healthcare provider.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile of Slow Deralin (Propranolol) by documenting severe, non-therapeutic manifestations primarily affecting the cardiac and central nervous systems. Emergency medical care is required immediately for any suspected overdose due to the potential for life-threatening outcomes.

Documented Overdose Manifestations

Overdose may present with signs of profound bradycardia (abnormally slow heart rate) and severe hypotension (extremely low blood pressure), escalating to atrioventricular conduction block or cardiac arrest. Non-cardiac effects documented in official labeling include severe bronchospasm, convulsions (seizures), confusion, and coma. Due to the sustained-release formulation, a prolonged monitoring period in a hospital setting may be required .

Required Emergency Actions

Category	Official Regulatory Action
Immediate Action	Seek immediate medical attention. Continuous cardiac and vital sign monitoring is required.
Antidote Status	Treatment is strictly symptomatic and supportive. Regulatory labels do not list a specific antidote.
Supportive Measures	Includes label-described procedures such as gastric lavage and administration of activated charcoal for recent ingestion.
Population Note	The risk of severe hypoglycemia is specifically documented for pediatric patients following an overdose.

The regulatory profile mandates that these severe physiological effects, such as cardiovascular depression and respiratory compromise, necessitate urgent professional medical intervention. The final management must be conducted in a highly monitored facility under continuous observation.

Therapeutic Uses of Slow Deralin

What Slow Deralin Treats: Main Uses and Benefits

The primary therapeutic role of this medication is to provide symptomatic relief and long-term stability across conditions marked by symptoms related to heightened physiological activity. This supportive use is generally applied in clinical settings that involve acute or unstable symptom patterns, contributing to easing the overall symptom load by managing physical manifestations linked to systemic imbalance.

Slow Deralin (Propranolol) is commonly used across conditions characterized by periods of heightened symptoms in both cardiovascular and neurological domains.

Therapeutic Scope and Benefits

The medication is relevant for easing discomfort in chronic cardiovascular disease management, including Hypertension, reducing the frequency of Angina Pectoris episodes, and Tachyarrhythmias. It is also applied to address Essential Tremor and for the prophylaxis of Migraine Headaches. In situations where patients experience physical distress from situational anxiety or Thyrotoxicosis, this treatment is generally considered relevant for moderating these symptoms.

This approach assists with supporting functional stability and may assist patients with maintaining a sense of stability during symptom fluctuations, contributes to supportive relief when symptoms interfere with routine activities.

“The supportive nature of this treatment is relevant in managing conditions where stability and event reduction are key goals.”

Quick Fact: Relief for Physical Stress

Category	Typical Symptom Relief
Cardiovascular	Reduced frequency of exertional chest pain; assists with stabilizing rapid heart rate.
Neurological	May assist in reducing the amplitude of involuntary shaking; contributes to reducing the frequency of migraine attacks.
Systemic	Moderation of physical symptoms like sweating and tremor associated with high stress.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Slow Deralin (Propranolol) — Official Regulatory Information

Eligibility Scope

Classification	Eligible Populations / Status	Excluded Populations / Status
Standard Use	Adults are the standard eligible population. Adolescents (typically over 12) may be eligible for adult dosing.	Contraindicated in patients with Bronchial Asthma, Cardiogenic Shock, Sick Sinus Syndrome, Second or Third-Degree Heart Block (without a pacemaker), or Untreated Pheochromocytoma.
Age-Related	Children may be eligible for specific indications (e.g., migraine prophylaxis) with individualized dosing.	The sustained-release capsule is not intended for use in children. Infants below 2 kg are strictly excluded from certain formulations.
Conditional Use	Patients with Significant Hepatic or Renal Impairment require caution at the start of treatment and careful dose selection.	Contraindicated in patients prone to Hypoglycemia (e.g., after prolonged fasting) and those with Severe Peripheral Arterial Circulatory Disturbances.
Reproductive Status	Pregnancy use necessitates monitoring of the neonate after delivery for bradycardia and hypoglycemia. Lactation involves excretion into breast milk.	Use is generally restricted or requires careful risk assessment based on labeled data.

Connection to the Overall Eligibility Profile

The official regulatory profile defines eligibility for Slow Deralin through absolute contraindications that exclude patients with underlying severe heart or respiratory conditions. Beyond these definitive exclusions, eligibility is structured by specific cautionary statements for populations whose status, such as age or impaired organ function, mandates individualized dose selection and monitoring, ensuring all constraints are formally documented.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Formal Regulatory Prohibitions and High-Risk Combinations

Co-administration with Thioridazine is formally prohibited due to the risk of dangerously increased exposure. The combination with non-dihydropyridine calcium channel blockers (e.g., Verapamil or Diltiazem) presents a documented high risk of severe pharmacodynamic effects, specifically profound bradycardia and hypotension. Other cardiac depressants, such as Digoxin, also carry a risk of additive heart rate slowing. Combinations with alpha-blockers (e.g., Prazosin) are associated with a documented risk of first-dose hypotension and syncope.

Metabolic and Exposure Alterations

The drug's metabolism involves the CYP450 system (CYP2D6, CYP1A2, CYP2C19). Inhibitors of these enzymes (e.g., Cimetidine, Fluoxetine) are documented to increase the plasma concentration of the drug. Conversely, Inducers (e.g., Rifampin, Phenytoin, Tobacco smoke) are documented to cause a decrease in drug levels, resulting in a loss of efficacy. Binding agents like Cholestyramine significantly reduce the amount absorbed. The effects of the drug may be increased in patients with hepatic impairment due to reduced clearance.

Administration Constraints and Substances

To ensure stable drug exposure, the medication must be taken consistently with food, as food intake enhances bioavailability. If discontinuing co-administration with Clonidine, the beta-blocker must be withdrawn gradually over several days before the Clonidine is discontinued, a procedural rule required to prevent rebound hypertension.

Mechanism of Action

Deralin is a competitive antagonist that modulates the effects of the beta-adrenergic receptor system, resulting in decreased nerve impulse frequency and modification of sympathetic signaling. The key mechanism is the competitive binding to the beta1 and beta2 receptors.

This interaction modulates sympathetic signal transmission by blocking the downstream signal cascade of adenylyl cyclase, which produces the second messenger cAMP. By inhibiting this intracellular cascade, Deralin reduces chronotropic effects and decreases overall sympathetic activity.

Furthermore, its membrane-stabilizing activity at higher concentrations may influence neuronal membrane excitability and contributes to the pharmacological effect. This overall effect alters signal transduction within target cells.

Dosage and Administration Information

How to Use Slow Deralin: General Administration Guidelines

Slow Deralin (Propranolol sustained-release capsule) is intended for oral administration and provides a mechanism for continuous delivery of the active ingredient over a prolonged period. Adherence to specific administration protocols is crucial for maintaining the intended therapeutic effect.

General Dosing and Schedule

The sustained-release capsule is typically taken once daily (q.d.). Dosing is initiated at a low level and gradually adjusted (titrated) by a healthcare provider to find the appropriate management dose.

Feature	General Administration Guidelines
Route of Administration	Oral
Standard Dosing	Typically starts at 80 mg once daily. Maintenance often ranges from 120 mg to 160 mg once daily.
Frequency	Once daily (q.d.).
Timing	Must be administered at the same time each day.

Administration Requirements

To ensure the proper function of the sustained-release mechanism, specific instructions for handling the capsule must be followed.

Ingestion Rule: The capsule must be swallowed whole. It is explicitly instructed not to crush, chew, or open the capsule, as this compromises the extended-release feature.
Food Timing: The medicine may be taken consistently with or without food.
Discontinuation: If treatment needs to be stopped, the dosage must be gradually reduced over a period of 1 to 2 weeks; abrupt cessation is advised against.

Population-Specific Considerations

For certain patient populations, the dose may require careful adjustment:

Hepatic Impairment: Patients with liver dysfunction may require a lower starting dose and careful dose titration due to altered clearance of the drug.
Older Adults: Treatment may be started at the lowest end of the dosing range and titrated cautiously.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Slow Deralin

Research Evidence for Use in Hypertension (High Blood Pressure)

Research exploring this medication was evaluated in large-scale, long-term Randomized Controlled Trials (RCTs). These studies examined outcomes monitoring physiological strain, focusing on measured changes in blood pressure levels and cardiovascular events. Studies describe patterns related to lower blood pressure levels. The research record for Propranolol specifically is limited regarding comparative evidence against many newer antihypertensive agents, and long-term effects for certain older adult populations are not fully established.

Studies Examining Migraine Prophylaxis

The research base for this medication was studied for conditions characterized by fluctuating or episodic manifestations, primarily involving placebo-controlled RCTs and systematic reviews. These studies monitored patient-reported outcomes describing perceived discomfort, focusing on episodic changes in monthly migraine days. Studies describe patterns observed, with research highlighting changes measured during the study period. Data for long-term outcomes and comparative evidence against all modern preventative agents remain insufficient.

Evidence Base for Essential Tremor and Related Motor Control

This medication was studied for conditions marked by functional limitations, such as Essential Tremor (ET). Evidence is largely derived from short-term RCTs that examined outcomes reflecting daily functioning, specifically tremor amplitude. Studies describe patterns related to outcomes reflecting daily functioning, particularly in upper limb tremor. However, findings indicate patterns related to limited changes measured in axial tremors (e.g., voice or head). Follow-up durations were limited, providing insight into initial response but not sustained patterns over many years.

Evidence on Short-Term Symptomatic Uses (Anxiety and Stress Symptoms)

Research has examined temporary physiological imbalance related to anxiety and stress, focusing on outcomes capturing phases of heightened symptom activity. Studies report how symptoms evolved in the observed populations, describing patterns related to physical discomfort. However, the evidence quality varies across studies, with many trials being older and small, and certainty remains low for its role in formal anxiety disorders. Comparative evidence against established anti-anxiety treatments is lacking.

Key Evidence Gaps and Areas of Uncertainty

Research highlights what is known—and what is still uncertain. A central limitation is that comparative evidence is lacking against many newer medications across all indications. Follow-up durations were limited in the studies for essential tremor and anxiety symptoms, meaning long-term effects are not fully established. Subgroup findings are uncertain, especially regarding outcomes in children with certain indications. Research does not provide individual predictions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Slow Deralin (FAQ)

Q: What are the official, approved uses for Slow Deralin?

According to official regulatory labeling (FDA/EMA), the approved uses for Slow Deralin include the management of hypertension (high blood pressure), migraine prophylaxis, and essential tremor. It is also approved for certain heart conditions and arrhythmias.

Q: Is Slow Deralin intended for short-term use, or is it a long-term treatment?

Official regulatory documents state that this medicine is used for the long-term management of ongoing conditions. Because of this, treatment should not be stopped abruptly. If a change in treatment is considered, official documents advise that the dosage is typically gradually reduced over one to two weeks, a procedure noted in the prescribing information.

Q: How does the slow release mechanism of the pill work inside the body?

Slow Deralin is an extended-release capsule, meaning it is specially engineered to release the medicine gradually over many hours. This controlled, prolonged release aims to maintain consistent and stable levels of the active ingredient in the bloodstream. This design is what differentiates it from immediate-release formulations.

Q: Is the onset of action slower for Slow Deralin compared to the instant version?

The sustained-release design of Slow Deralin results in a slower rate of absorption of the medicine into the bloodstream compared to the instant-release tablet. This is a characteristic of the formulation that contributes to the long duration of action.

Q: How long does Slow Deralin stay in the system after the last dose?

For a person with healthy liver and kidney function, the active ingredient typically has a half-life of approximately 3 to 6 hours. Clearance of the medication relies primarily on metabolism by the liver.

Q: How is the long-term safety of Slow Deralin monitored by regulatory bodies?

Regulatory authorities continuously monitor the long-term safety profile of medicines after they are released to the public. They use programs such as postmarketing surveillance and national reporting systems established for collecting safety information to analyze suspected adverse reactions that are reported.

Q: Is it necessary to have regular blood tests while taking Slow Deralin?

Official documents advise that blood pressure and heart rate should be routinely monitored during treatment. Caution is advised for patients with liver or kidney impairment, and specific monitoring (which may include tests) is often necessary in these populations, as these conditions can affect how the medicine is cleared from the body.

Q: What is the likelihood of developing a chronic cough or breathing issues while on Slow Deralin?

Regulatory documents explicitly state that this medicine is contraindicated (must not be used) in patients with conditions like bronchial asthma. Difficulty breathing, such as bronchospasm (difficulty breathing or wheezing), is a serious side effect that is documented to require immediate medical attention.

Q: How does Slow Deralin affect the body's response to physical exercise?

The active ingredient in Slow Deralin works by reducing the heart's response to natural stress hormones, like adrenaline. This physiological action typically results in a measured reduction in heart rate and force during physical activity or exertion, as described in the clinical pharmacology data.

Q: Can taking Slow Deralin affect a person's ability to drive or operate machinery?

Official warnings indicate that common side effects include dizziness, tiredness, and disturbed sleep. Due to these possible effects, official warnings describe that patients may need to avoid driving or operating machinery until they understand how the medication affects them.

Q: Is Slow Deralin known to cause weight gain or weight loss?

Post-marketing reports associated with the drug indicate that weight gain may occur in some patients taking beta-blockers. As with many medications, the exact effect can vary from person to person and is influenced by individual health factors.

Q: Are there any common foods or drinks that should be avoided when using Slow Deralin?

According to official product information, Slow Deralin may be taken consistently with or without food. However, taking the medicine with food can enhance its absorption into the body. To maintain stable therapeutic levels, official guidance is to take the medicine the same way each time (e.g., always with food, or always without).

Q: Can I use alcohol while taking Slow Deralin?

Official product warnings advise patients to discuss alcohol use with a healthcare provider before use. In general, taking alcohol with this medicine may increase the effects of the drug.

Q: Can you take pain relievers like ibuprofen while being treated with Slow Deralin?

Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen may reduce the effectiveness of Slow Deralin in lowering blood pressure. This potential interaction is documented in official labeling. Official guidance states that patients should consult a healthcare professional before combining pain relievers like NSAIDs with this medicine.

Q: Does Slow Deralin interact with commonly used cold and flu medications?

Official drug interaction warnings indicate that certain over-the-counter cold and flu products can be problematic. Specifically, products containing stimulants or decongestants may raise blood pressure and potentially counteract the intended effects of Slow Deralin.

Q: Does Slow Deralin interact with over-the-counter vitamins or mineral supplements?

Official labeling indicates that some multivitamins that contain minerals may reduce the medicine’s overall effectiveness. Official information notes that separating the administration times of the medicine and the supplement by at least two hours may be necessary to prevent reduced effectiveness.

Q: Are there any reported interactions between Slow Deralin and herbal supplements?

Official interaction guidance emphasizes that all products, including prescription medications, nonprescription medicines, vitamins, and herbal products, should be disclosed to the healthcare provider due to the potential for interactions.

Q: Can Slow Deralin be taken with antacids or medicines for heartburn?

Some common antacids, particularly those containing aluminum hydroxide, are documented to reduce the body's absorption of Slow Deralin. Official information indicates that separating the administration times of the antacid and this medicine may be required to minimize potential interactions.

Q: Is it true that Slow Deralin can impact sexual function?

Adverse events related to sexual function are documented in official post-marketing reports for this medicine. These documented issues include changes in libido and erectile dysfunction.

Q: Can Slow Deralin affect the results of common medical diagnostic tests?

Official prescribing information notes that this medicine has been reported to potentially interfere with the results of certain medical diagnostic tests. Specifically, it can interfere with the determination of catecholamines and the estimation of serum bilirubin in laboratory tests.

How should Slow Deralin be stored and disposed of?

How to Store and Dispose of Slow Deralin

Official regulatory guidelines define specific conditions for storing and disposing of Propranolol Sustained Release Capsules (Slow Deralin) to ensure product stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, between 20 C and 25 C.
Protection	Keep in the original container, tightly closed, and protected from moisture.
Child Safety	Keep this medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Slow Deralin must not be disposed of using household waste or by being thrown into wastewater. Disposal must be carried out according to local requirements. Patients are instructed to consult a pharmacist for guidance on how to properly discard any medicine they no longer need.

Slow Deralin